Latest From Cigna Corp.
Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.
Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.
Approach designed to avoid price “shock” when coverage for Luxturna or Zolgensma is requested. Plans would agree to certain per member per month payments to enroll in the program, which would cover both plan and patient costs for gene therapy.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Cigna Corp.
- Senior Management
David Cordani, Pres. & CEO
Eric Palmer, EVP & CFO
Alan Muney, MD, CMO, EVP, Total Health & Network
- Contact Info
Phone: (860) 226-6000
900 Cottage Grove Rd.
Bloomfield, CT 06002
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.